Business Wire

Retailers Struggle To Capture Long-Term Value From Their Peak App Acquisition Gains

3.4.2024 16:00:00 EEST | Business Wire | Press release

Share

For brands that experience a flood of new installs during peak shopping days like Black Friday, the secret to capturing the value of that effort is what happens next. Airship, the mobile app experience company, today shared findings that indicate peak installers are not all they’re cracked up to be.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403543802/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Airship’s aggregate analysis shows that customers adding shopping apps at the height of the holiday frenzy see lower weekly retention rates than pre-holiday customers by Week 4. (Graphic: Airship)

For apps, peak install periods are the most significant value creation opportunities — and also the most costly due to more paid install competition. To quantify the opportunity and bring greater urgency to value-capture efforts, Airship analyzed mobile app lifecycle and retention data aggregated across more than 60 million new shopping apps first installed between Oct. 1 and Nov. 27 (Cyber Monday), 2023. Key app install findings include:

  • Peak Day: Going on a decade, Black Friday is the top day of the year for customers to install a shopping app — double the daily average rate for October.
  • Peak Week: Six of the top seven peak shopping app install days were Nov. 19-25, which is much more tightly grouped than prior years. This peak week saw 40% more app installs than October’s weekly average.
  • Pre-Holiday: Five of the seven lowest daily app install days were Oct. 1-7, providing a one-week pre-holiday cohort to compare against peak-week customers.

“When acquisition costs are high, customer lifespans need a long enough runway to amortize those costs and generate returns. In other words, brands must hold on to newly acquired customers for dear life,” (Forrester Research, Inc., “Unlock Your Revenue Growth Potential,” June 4, 2023).

Wake Up, Retailers!

The core finding of Airship’s retention analysis should be a wake-up call to retailers everywhere: by Week 3 after install, any advantage gained in this merriest time of year is wiped out as peak-week customers go on to average 18% lower weekly retention rates than customers acquired pre-holiday. By Week 15, peak-week retention rates plummet further.

A three percentage point difference at Week 15 — +27% greater than peak week’s rate — can equate to massive future value. Research done by Frederick Reichheld of Bain & Company found a 5% increase in retained customers yields 25-95% more profit. More recently, Google/Ipsos found that 74% of retail decision-makers say investing in mobile apps is key to driving profitability and important for long-term success (85%).

Despite the peak growth opportunity and overall importance of apps, the two cohorts exhibit a similar retention pattern, suggesting retailers don’t treat peak-week app customers any differently from pre-holiday customers — despite the holiday frenzy’s urgent, transactional focus. Essentially, retailers allow peak-week customers to remain transactionally focused, which is reflected in lower retention rates before Christmas has even arrived. In addition, both cohorts see 38% of new users only open the app once within the analysis time frame (Week 0), helping to account for the Week 1 retention rate.

Capturing Value Requires Advancing Customers Through the App Lifecycle

Rather than focusing on rear-view retention rates, Airship recommends that retailers focus on advancing customers through the mobile app lifecycle — from acquisition to activation, engagement and loyalty. To help, Airship compared the peak-week and pre-holiday cohorts with a subset of metrics used to gauge and optimize progress through the activation and engagement lifecycle stages.

During activation (Day 1-30 after download), the most successful apps focus on understanding customers’ preferences and interests while gaining ways to communicate with them. Identified User Coverage, which is the number of devices with a unique customer ID divided by total devices, is a key metric as it allows brands to link customer data from prior interactions and across channels to better personalize and orchestrate future interactions. Customers gained during pre-holiday have 3% higher Identified User Coverage rates than peak-week adopters. Perhaps due to seasonality and promotions or rewards requiring registration, both cohorts come in above the February shopping category averages: 10% higher for pre-holiday customers and 7% higher for peak week.

Metric comparisons for the engagement lifecycle stage included Average Sessions Per Active User, Average Session Length (in minutes per month) and Airship’s Engagement Score, which indicates how many monthly active users return on a daily basis.

  • Pre-holiday customers’ February 2024 Engagement Scores are 8% higher than the shopping category average and 14% higher than peak-week customers’, further illustrating the transitory, transactional nature of the latter cohort.
  • Pre-holiday customers also lead in Average Sessions Per Active User, with February 2024 totals 17% higher than peak-week customers and 9% higher than the shopping category average.
  • The only engagement metric where peak-week customers outperformed pre-holiday customers was Average Session Length, with .006 more monthly minutes in February 2024 (+.4%). Both cohorts are 9% below the February shopping category average for session duration.

For best practices, additional metrics and benchmarks to compare activation and engagement performance across app store categories, please download Airship’s reports: Mobile Lifecycle Benchmark: Activation and Mobile Lifecycle Benchmark: Engagement. Registration is now open for Airship’s April 11 webinar, Capture Customer Attention: 3 Strategies in 30 Days.

“Customers clearly flock to shopping apps to get the best deals, earn rewards and gain exclusive access, but it’s up to retailers to turn installs and first transactions into ongoing use where real value accumulates,” said Thomas Butta, Chief Strategy and Marketing Officer, Airship. “Brands should continually optimize onboarding experiences and reinforce value throughout the lifecycle and across channels for different types of customers. Above all, they need to capture customers’ attention in moments that matter — which calls for in-app experiences tailored to the individual, so brands can continually grow customer understanding, drive engagement and build loyalty over time.”

Methodology

Airship analyzed aggregate data from shopping apps with at least 100,000 monthly active users that also saw new installs and at least 1,000 device sessions within both the peak-week and pre-holiday cohorts. Analysis included 63 million new app users gained between October 1 and November 27, 2023. One-week pre-holiday and peak-week cohorts were established to track and compare monthly activation and engagement metrics through February 2024 and weekly retention rates through Week 15 following Week 0 installation.

About Airship

No one knows more, does more, or cares more than Airship when it comes to helping brands master mobile app experience (MAX).

From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, no-code native app experience creation and App Store Optimization (ASO).

Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital center of customer experience, brand loyalty and monetization.

With the Airship App Experience Platform and Gummicube’s ASO technology and expertise, brands now have a complete set of solutions to optimize the entire mobile app customer journey – from the point of discovery to loyalty – driving greater value for everyone involved.

For more information, visit www.airship.com, read our blog or follow us on X (formerly Twitter), LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Deidre Wright
Airship
+1 415-223-0832
deidre.wright@airship.com

Kali Myrick
Kali Myrick Communications
+1 503-580-4645
kali@kalimyrick.com

EMEA:
Ana Williams
Airship
+44 (0)20 3405 5160
press@airship.com

Pauline Delorme
Tyto PR
+44 (0)20 3934 8882
Airship@tytopr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye